• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, October 8, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Study: Pharmacies should proactively offer naloxone to all patients who meet evidence-based criteria

Bioengineer by Bioengineer
March 23, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

BOSTON– Pharmacies should proactively offer naloxone, a drug that blocks or reverses the effects of overdose, to patients taking opioid medications through universal opt-out strategies in an effort to get the life-saving drug into the hands of more people who need it, according to a new study out of Boston Medical Center (BMC).

The US Department of Health and Human Services named expanding access to the rescue medication naloxone (known also by the brand name Narcan) one of three main strategies to address the opioid crisis. Research has found educating and providing naloxone to people who are at risk of witnessing or experiencing an overdose leads to a 30-50 percent decrease in opioid death rates.

Currently, pharmacists in Massachusetts and Rhode Island can provide naloxone without a prescription. However, the study found that many patients are reluctant to ask for naloxone or they are unaware of its availability, while pharmacists are concerned about the implications of offering it without being asked.

"There's this tension between patients who are afraid of the stigma associated with asking for naloxone, and pharmacists who worry about damaging relationships or breaking trust with patients by offering it," said Traci Green, PhD, MSc, epidemiologist and associate director of the Injury Prevention Center at BMC who served as lead author of the study. "It's these fears that hold pharmacists back from offering naloxone to people who may need it for themselves or their family".

After conducting a series of eight focus groups in two states with over 60 pharmacists, pain patients, current and former drug users, and family members of people who use opioids, researchers found consistent support for an "opt-out" model of offering naloxone in the pharmacy, rather than the current model that has people asking for it at the pharmacy counter–where too few do. The opt-out model universally offers naloxone to those obtaining opioid prescriptions or those with identifiable medication-related risks, such as patients taking high doses of opioids for pain or for opioid use disorder, or those who are co-prescribed opioids and sleep aids or anxiety drugs. It would also target those who pick up such prescriptions for their family members.

"Most overdoses occur at home or with a loved one close by. With expanded naloxone access in the pharmacy setting, we have the opportunity to give people the choice to keep themselves and their family safe, and reduce the stigma of getting naloxone and of addiction. Our study suggests that by giving pharmacists the model and language to do so, they have the power to save a life with naloxone" said Green, who is also an associate professor of emergency medicine at Boston University School of Medicine.

The study is published in the Journal of American Pharmacists Association and is part of the larger MOON study, led by Dr. Green and others at BMC and in collaboration with researchers at Boston University, Lifespan Hospitals of Rhode Island and the University of Rhode Island. The three-year project is funded by the Agency for Healthcare Research & Quality, which is working with local pharmacies in Massachusetts and Rhode Island to determine the best way to provide naloxone in the pharmacy setting.

###

About Boston Medical Center

Boston Medical Center is a private, not-for-profit, 493-bed, academic medical center that is the primary teaching affiliate of Boston University School of Medicine. It is the largest and busiest provider of trauma and emergency services in New England. Committed to providing high-quality health care to all, the hospital offers a full spectrum of pediatric and adult care services including primary and family medicine and advanced specialty care with an emphasis on community-based care. Boston Medical Center offers specialized care for complex health problems and is a leading research institution, receiving more than $119 million in sponsored research funding in fiscal year 2015. It is the 11th largest recipient of funding in the U.S. from the National Institutes of Health among independent hospitals. In 1997, BMC founded Boston Medical Center Health Plan, Inc., now one of the top ranked Medicaid MCOs in the country, as a non-profit managed care organization. It does business in Massachusetts as BMC HealthNet Plan and as Well Sense Health Plan in New Hampshire, serving more than 315,000 people, collectively. Boston Medical Center and Boston University School of Medicine are partners in the Boston HealthNet – 14 community health centers focused on providing exceptional health care to residents of Boston. For more information, please visit http://www.bmc.org.

Media Contact

Jessica Lyons
[email protected]
714-638-6838
@BostonUNews

http://www.bmc.org

############

Story Source: Materials provided by Scienmag

Share12Tweet7Share2ShareShareShare1

Related Posts

Gut Microbiota Alterations Determine Susceptibility to AIG-Associated Neuroendocrine Tumors

October 8, 2025

Circular RNAs in Mammalian Follicle Development: Insights

October 8, 2025

Surgical Menopause May Prompt Early Workforce Exit in Women, But Hormone Therapy Shows Promise

October 8, 2025

Birds Flourish Despite Pollution from Persistent ‘Forever’ Chemicals

October 8, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1045 shares
    Share 418 Tweet 261
  • New Study Reveals the Science Behind Exercise and Weight Loss

    99 shares
    Share 40 Tweet 25
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    95 shares
    Share 38 Tweet 24
  • Ohio State Study Reveals Protein Quality Control Breakdown as Key Factor in Cancer Immunotherapy Failure

    78 shares
    Share 31 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Gut Microbiota Alterations Determine Susceptibility to AIG-Associated Neuroendocrine Tumors

Circular RNAs in Mammalian Follicle Development: Insights

Surgical Menopause May Prompt Early Workforce Exit in Women, But Hormone Therapy Shows Promise

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.